Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The War on Diabetic Retinopathy: Where Are We Now?

The War on Diabetic Retinopathy: Where Are We Now? Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 REVIEW ARTICLE Tien Y. Wong, MD, PhD y and Charumathi Sabanayagam, MD, PhD y Of all the diabetes complications, DR exerts a significant Abstract: Diabetic retinopathy (DR), a major cause of blindness in public health and clinical impact for a number of reasons. One working-age adults, is emerging as a major public health issue worldwide, third of those with diabetes have DR, with 1 in 10 having vision- in particular in low- and middle-income countries (LMIC). Traditionally, threatening levels of DR. Despite progress in understanding the the management of DR has been on tertiary-level treatment (eg, laser, disease and availability of new treatments, DR remains the most anti-VEGF injections and surgery) in specialized settings by highly common cause of blindness in the economically active, working- trained ophthalmologists on individual patients. To win the war on age population, exerting a disproportionate impact on society. In DR, a paradigm shift in strategic focus and resources must be made 2010, DR ranked the fifth most common cause of blindness and from such tertiary treatment toward primary and secondary prevention, visual impairment accounting for up to 4.5 million people to which are broader, more impactful, and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Asia-Pacific Journal of Ophthalmology Wolters Kluwer Health

The War on Diabetic Retinopathy: Where Are We Now?

Loading next page...
 
/lp/wolters-kluwer-health/the-war-on-diabetic-retinopathy-where-are-we-now-AYzvZD0WZ6
Publisher
Wolters Kluwer Health
ISSN
2162-0989
eISSN
2475-5028
DOI
10.1097/APO.0000000000000267
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/apjoo by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/02/2020 REVIEW ARTICLE Tien Y. Wong, MD, PhD y and Charumathi Sabanayagam, MD, PhD y Of all the diabetes complications, DR exerts a significant Abstract: Diabetic retinopathy (DR), a major cause of blindness in public health and clinical impact for a number of reasons. One working-age adults, is emerging as a major public health issue worldwide, third of those with diabetes have DR, with 1 in 10 having vision- in particular in low- and middle-income countries (LMIC). Traditionally, threatening levels of DR. Despite progress in understanding the the management of DR has been on tertiary-level treatment (eg, laser, disease and availability of new treatments, DR remains the most anti-VEGF injections and surgery) in specialized settings by highly common cause of blindness in the economically active, working- trained ophthalmologists on individual patients. To win the war on age population, exerting a disproportionate impact on society. In DR, a paradigm shift in strategic focus and resources must be made 2010, DR ranked the fifth most common cause of blindness and from such tertiary treatment toward primary and secondary prevention, visual impairment accounting for up to 4.5 million people to which are broader, more impactful, and

Journal

The Asia-Pacific Journal of OphthalmologyWolters Kluwer Health

Published: Nov 1, 2019

There are no references for this article.